4BIO Capital

Philadelphia, Pennsylvania
cb
Founded:2016
Firm Location:Philadelphia, Pennsylvania • London • Dubai, United Arab Emirates • United Kingdom
Investor Firms That Co-Invest with 4BIO Capital
New Enterprise Associates (NEA)F-Prime Capital PartnersAbingworth5am VenturesNorthpond VenturesRemiges VenturesvenBioTakeda VenturesBusiness Growth FundAstellas Venture ManagementPureos Bioventures
4BIO Capital Team
Photo of Nikolai Denisov, Investor at 4BIO Capital
Nikolai Denisov
4BIO Capital·Investor
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Dubai (United Arab Emirates)
Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed)
to see your intro paths to Nikolai
Photo of Alexandra Gajdosova, Analyst at 4BIO Capital
Alexandra Gajdosova
4BIO Capital·Analyst
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in United Kingdom
Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed)
to see your intro paths to Alexandra
Photo of Natalie Johnston, Associate at 4BIO Capital
Natalie Johnston
4BIO Capital·Associate
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in London
Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in BioTech (Series A), Investors in London (Other Lists), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed)
to see your intro paths to Natalie
Photo of Andrew Kozlov, Managing Partner at 4BIO Capital
Andrew Kozlov
4BIO Capital·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in London
Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in London (Other Lists), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A)
to see your intro paths to Andrew
Photo of Dima Kuzmin, Managing Partner at 4BIO Capital
Dima Kuzmin
4BIO Capital·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in London
Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in London (Other Lists), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A)
to see your intro paths to Dima
Photo of Brian McVeigh, Venture Partner at 4BIO Capital
Brian McVeigh
4BIO Capital·Venture Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Philadelphia (PA)
Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in New York City (Other Lists), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A)
to see your intro paths to Brian
Photo of Kieran Mudryy, Partner at 4BIO Capital
Kieran Mudryy
4BIO Capital·Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in London
Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in London (Other Lists), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed)
to see your intro paths to Kieran
Photo of Owen Smith, Partner at 4BIO Capital
Owen Smith
4BIO Capital·Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in London
Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in London (Other Lists), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed)
to see your intro paths to Owen